Johnson & Johnson IMBRUVICA — Percent Change (as a percent) increased by 11.5% to -6.9% in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 27.4%, from -9.5% to -6.9%. This is a positive signal — higher values indicate stronger performance for this metric.
Positive growth indicates expanding market share or increased patient utilization, whereas negative growth suggests potential market share erosion, pricing pressure, or declining clinical relevance.
This metric measures the period-over-period percentage growth or decline in net sales for a specific pharmaceutical prod...
Comparable to product-level revenue growth rates reported by major pharmaceutical companies to track the performance of key growth drivers versus legacy products.
jnj_segment_imbruvica_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 17.7% | 3.5% | -7.7% | -13.1% | -14.6% | -1.6% | -20.3% | -13.2% | -11.3% | -5.2% | -8.5% | -6.8% | -0.1% | -9.5% | -4.5% | -7.8% | -6.9% |
| QoQ Change | — | -80.2% | -320.0% | -70.1% | -11.5% | +89.0% | <-999% | +35.0% | +14.4% | +54.0% | -63.5% | +20.0% | +98.5% | <-999% | +52.6% | -73.3% | +11.5% |
| YoY Change | — | — | — | -174.0% | -517.1% | — | -163.6% | -0.8% | +22.6% | +74.4% | +35.6% | +39.8% | — | -82.7% | +47.1% | -14.7% | +27.4% |